Quantum BioPharma Ltd. (NASDAQ: QNTM), a biopharmaceutical company developing therapies for neurodegenerative and metabolic disorders, has signed a Study Start-Up Agreement with the clinical research business of Thermo Fisher Scientific to implement the Phase 2 trial of Lucid-MS, its lead drug candidate for multiple sclerosis (MS). The agreement moves the innovative treatment from planning into execution, according to the company.
Most MS drugs work by quieting the immune system. Lucid-MS is designed around a proprietary, novel neuroprotective approach that targets demyelination—the damage to the protective sheath around nerves—rather than solely modulating the immune system. This distinction could represent a new way to treat MS, a chronic disease in which the immune system attacks the myelin sheath, leading to nerve damage and disability.
Thermo Fisher’s clinical research business is a leading global contract research organization with expertise in central nervous system and MS studies. Its involvement provides the infrastructure and specialized knowledge needed to rigorously test Lucid-MS in a Phase 2 setting, which will assess the drug’s efficacy and safety in patients.
For investors and the biopharmaceutical industry, the partnership signals confidence in Quantum BioPharma’s platform and a significant step toward potentially bringing a new class of MS therapy to market. If successful, Lucid-MS could offer an alternative for patients who do not respond adequately to existing immune-modulating treatments. The global MS market is substantial, and a neuroprotective approach could address an unmet need by directly protecting nerve fibers.
Quantum BioPharma is listed on NASDAQ under the ticker QNTM. The company’s Quantum BioPharma (NASDAQ: QNTM) newsroom, available at https://ibn.fm/QNTM, provides the latest updates. The announcement was distributed through InvestorWire, a specialized communications platform focused on wire-grade press release syndication. InvestorWire is one of more than 75 brands within the Dynamic Brand Portfolio at IBN, which offers services including article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions.
The Phase 2 trial will be a critical test for Lucid-MS. Success could validate Quantum BioPharma’s neuroprotective strategy and attract further investment, while failure would delay hopes for a new MS treatment. The partnership with Thermo Fisher underscores the importance of rigorous clinical research in bringing novel therapies to patients. For now, the agreement marks a tangible milestone in Quantum BioPharma’s efforts to advance its pipeline. Terms of the agreement were not disclosed. More details are available in the full announcement, which can be accessed via Read More>>.
